Daily Cardiology Research Analysis
Three high-impact basic-to-translational cardiology studies stand out today: (1) modified mRNA therapy restores cardiac function in desmocollin‑2–deficient mouse models of arrhythmogenic right ventricular cardiomyopathy; (2) the human heart exhibits intrinsic ketogenic capacity via HMGCS2 that is required for NAD+ repletion to rescue HFpEF; and (3) epigenetic rewiring by SETD2 drives lipotoxic injury in cardiometabolic HFpEF, revealing a therapeutic chromatin target. Together, they spotlight RNA
Summary
Three high-impact basic-to-translational cardiology studies stand out today: (1) modified mRNA therapy restores cardiac function in desmocollin‑2–deficient mouse models of arrhythmogenic right ventricular cardiomyopathy; (2) the human heart exhibits intrinsic ketogenic capacity via HMGCS2 that is required for NAD+ repletion to rescue HFpEF; and (3) epigenetic rewiring by SETD2 drives lipotoxic injury in cardiometabolic HFpEF, revealing a therapeutic chromatin target. Together, they spotlight RNA therapeutics, cardiac metabolism, and chromatin regulation as converging avenues for next‑generation heart failure care.
Research Themes
- RNA therapeutics for inherited cardiomyopathies
- Cardiac ketogenesis and NAD+ signaling in HFpEF
- Epigenetic/chromatin regulation of lipotoxicity in heart failure
Selected Articles
1. Modified mRNA Treatment Restores Cardiac Function in Desmocollin-2-Deficient Mouse Models of Arrhythmogenic Right Ventricular Cardiomyopathy.
Using modified mRNA targeting desmocollin‑2 deficiency, the authors restored desmosomal function and improved cardiac performance in mouse models of ARVC, bridged by human genetic discovery. This provides first-in-class preclinical evidence that mRNA replacement can treat inherited cardiomyopathy by correcting structural protein deficits.
Impact: Introduces a translational RNA therapy paradigm for desmosomal cardiomyopathy with robust functional rescue in vivo. It opens a therapeutic class beyond gene editing and small molecules for structural cardiomyopathies.
Clinical Implications: While preclinical, this work supports clinical development of modified mRNA replacement for ARVC and potentially other desmosomal cardiomyopathies. It suggests a feasible delivery/efficacy path to correct structural protein deficits without permanent genome alteration.
Key Findings
- Genetic discovery of a novel DSC2 (desmocollin‑2) variant linked to ARVC and functional validation in models.
- Modified mRNA delivery restored desmosomal protein expression and improved right ventricular function in Dsc2‑deficient mice.
- Therapeutic mRNA replacement mitigated arrhythmogenic substrate and structural dysplasia, demonstrating disease-modifying potential.
Methodological Strengths
- Translational pipeline from human exome sequencing to mechanistic preclinical rescue
- In vivo functional endpoints demonstrating structural and electrophysiological improvement
Limitations
- Preclinical mouse data; human safety, dosing, and delivery need evaluation
- Durability of mRNA therapy and immune responses were not fully established
Future Directions: Optimize cardiac-targeted mRNA delivery, assess long-term efficacy/safety, and design early-phase trials for ARVC and broader desmosomal cardiomyopathies.
BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart disease characterized by irregular rhythms and right ventricular dysplasia. Sequence variations in desmosomal protein-encoding genes are linked to ARVC development. Effective treatments for ARVC are lacking. Whereas mRNA-based therapies have shown efficacy in humans, their therapeutic potential for inherited cardiomyopathies remains unclear. METHODS: Whole-exome sequencing identified a novel CONCLUSIONS: Our study reveals novel mechanisms of ARVC caused by
2. The Heart Has Intrinsic Ketogenic Capacity that Mediates NAD
The study establishes that human myocardium has intrinsic ketogenic capacity via HMGCS2 and that NAD+ repletion rescues HFpEF by deacetylating and restoring HMGCS2 activity, normalizing lipid metabolism and mitochondrial function. Cardiomyocyte‑specific HMGCS2 is necessary for the therapeutic effect, linking cardiac ketogenesis to HFpEF treatment response.
Impact: Provides first direct evidence of cardiac ketogenesis in humans and mechanistic necessity of HMGCS2 for NAD+ therapy in HFpEF. It reframes metabolic therapeutics and biomarker strategies for HFpEF.
Clinical Implications: Supports metabolic precision approaches in HFpEF (e.g., NAD+ augmentation) and suggests HMGCS2 status could stratify responders. It motivates therapeutic combinations that enhance cardiac ketogenesis or modulate protein acetylation.
Key Findings
- Human hearts produce ketones intrinsically via HMGCS2; enzyme acetylation reduces activity.
- NAD+ repletion deacetylates and restores HMGCS2, enhances fatty acid oxidation, and rescues HFpEF function.
- Cardiomyocyte-specific HMGCS2 knockdown abrogates the therapeutic benefit of NAD+ repletion in HFpEF.
Methodological Strengths
- Integration of human myocardium, transcardiac sampling, multi-omics and isotope tracing
- Conditional cardiomyocyte-specific genetic model proving necessity of HMGCS2
Limitations
- Translational bridge to clinical NAD+ interventions requires controlled trials
- Heterogeneity of human HFpEF etiology may influence generalizability
Future Directions: Develop biomarkers of cardiac ketogenesis/HMGCS2 activity, test NAD+ augmentation and deacetylation modulators in HFpEF trials, and map patient subgroups most likely to benefit.
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has overtaken heart failure with reduced ejection fraction as the leading type of heart failure globally and is marked by high morbidity and mortality rates, yet with only a single approved pharmacotherapy: SGLT2i (sodium-glucose co-transporter 2 inhibitor). A prevailing theory for the mechanism underlying SGLT2i is nutrient deprivation signaling, of which ketogenesis is a hallmark. However, it is unclear whether the canonical ketogenic enzyme, HMGCS2 (3-hydroxy-3-methylglutaryl-coenzyme A synthase 2), plays any cardiac role in HFpEF pathogenesis or therapeutic response. METHODS: We used human myocardium, human HFpEF and heart failure with reduced ejection fraction transcardiac blood sampling, an established murine model of HFpEF, ex vivo Langendorff perfusion, stable isotope tracing in isolated cardiomyocytes, targeted metabolomics, proteomics, lipidomics, and a novel cardiomyocyte-specific conditional HMGCS2-deficient model that we generated. RESULTS: We demonstrate, for the first time, the intrinsic capacity of the human heart to produce ketones via HMGCS2. We found that increased acetylation of HMGCS2 led to a decrease in the enzyme's specific activity. However, this was overcome by an increase in the steady-state levels of protein. Oxidized form of nicotinamide adenine dinucleotide repletion restored HMGCS2 function via deacetylation, increased fatty acid oxidation, and rescued cardiac function in HFpEF. Critically, using a conditional, cardiomyocyte-specific HMGCS2 knockdown murine model, we revealed that the oxidized form of nicotinamide adenine dinucleotide is unable to rescue HFpEF in the absence of cardiomyocyte HMGCS2. CONCLUSIONS: The canonical ketogenic enzyme, HMGCS2, mediates the therapeutic effects of the oxidized form of nicotinamide adenine dinucleotide repletion in HFpEF by restoring normal lipid metabolism and mitochondrial function.
3. Chromatin Rewiring by SETD2 Drives Lipotoxic Injury in Cardiometabolic HFpEF.
The study identifies SETD2‑driven H3K36me3 chromatin remodeling as a causal program for lipotoxic injury in cardiometabolic HFpEF. Cardiomyocyte SETD2 is upregulated, and H3K36me3 is enriched at lipid metabolism genes; targeting SETD2 attenuates pathologic lipid handling, nominating epigenetic modulation as a therapeutic strategy.
Impact: Connects a defined chromatin writer (SETD2) to lipid metabolic derangements in HFpEF, opening a tractable epigenetic target in a syndrome with few options. It integrates transcriptional regulation with metabolic injury.
Clinical Implications: Suggests that SETD2/H3K36me3 modulation could reduce lipotoxic stress in HFpEF, complementing metabolic therapies. Encourages biomarker development around chromatin marks and lipid signatures for patient stratification.
Key Findings
- Cardiomyocyte SETD2 is upregulated in cardiometabolic HFpEF, with H3K36me3 enrichment at lipid metabolism gene promoters.
- Chromatin and transcriptomic profiling link SETD2 activity to lipotoxic metabolic programs in HFpEF.
- Targeting/abrogating SETD2 signaling mitigates lipotoxic injury, nominating SETD2 as a therapeutic target.
Methodological Strengths
- ChIP‑seq and RNA‑seq integration to map chromatin‑transcription coupling
- Cardiomyocyte‑specific genetic manipulation to test causality
Limitations
- Predominantly preclinical; pharmacologic SETD2 modulation in vivo requires safety/efficacy studies
- HFpEF heterogeneity may necessitate careful patient selection
Future Directions: Develop small-molecule or epigenetic editing approaches to modulate SETD2/H3K36me3; define lipidomic and chromatin biomarkers predicting response in HFpEF.
BACKGROUND: Cardiometabolic heart failure with preserved ejection fraction (cHFpEF) is a highly prevalent and deadly condition. Histone 3 trimethylation at lysine 36 (H3k36me3)-a chromatin signature induced by the histone methyltransferase SETD2 (SET domain containing 2)-correlates with changes in gene expression in human failing hearts; however, its role remains poorly understood. This study investigates the role of SETD2 in cHFpEF. METHODS: Chromatin immunoprecipitation sequencing and RNA sequencing were used to investigate H3k36me3-related transcriptional regulation. Mice with cardiomyocyte-specific deletion of SETD2 (c-SETD2 RESULTS: SETD2 was upregulated in cHFpEF mouse hearts, and its chromatin mark H3k36me3 was involved in lipid metabolism and highly enriched on the promoter of the CONCLUSIONS: Targeting SETD2 might prevent lipotoxic injury in cHFpEF.